[
  {
    "ts": null,
    "headline": "NYLI Winslow Large Cap Growth Fund Q1 2025 Commentary",
    "summary": "NYLI Winslow Large Cap Growth Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=f555296355d4c2b39401f981100486b0e3aac83cd9a6706de47d93ce4af7559b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751499000,
      "headline": "NYLI Winslow Large Cap Growth Fund Q1 2025 Commentary",
      "id": 135719661,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f555296355d4c2b39401f981100486b0e3aac83cd9a6706de47d93ce4af7559b"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?",
    "summary": "The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finnhub.io/api/news?id=98e83eefe91e73f7289104f4b4d28bc18faf408ec7568d72c1ffc003b766f36d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751463003,
      "headline": "Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?",
      "id": 135714089,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "url": "https://finnhub.io/api/news?id=98e83eefe91e73f7289104f4b4d28bc18faf408ec7568d72c1ffc003b766f36d"
    }
  },
  {
    "ts": null,
    "headline": "Will AbbVie's Acquisition Spree Aid Pipeline Growth?",
    "summary": "ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.",
    "url": "https://finnhub.io/api/news?id=323e3788c281ffd783e10e7ffb52dc8e71c27b8c917a971f6f8edbeb356d1644",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751460360,
      "headline": "Will AbbVie's Acquisition Spree Aid Pipeline Growth?",
      "id": 135712714,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.",
      "url": "https://finnhub.io/api/news?id=323e3788c281ffd783e10e7ffb52dc8e71c27b8c917a971f6f8edbeb356d1644"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers: The Bubble Implosion Looks Far From Over (Downgrade)",
    "summary": "Hims & Hers: The Bubble Implosion Looks Far From Over (Downgrade)",
    "url": "https://finnhub.io/api/news?id=a3678000cae0270a50d50d5933f2507a62627851b95a0e8f5cc669ba3ff108f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751459400,
      "headline": "Hims & Hers: The Bubble Implosion Looks Far From Over (Downgrade)",
      "id": 135713770,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a3678000cae0270a50d50d5933f2507a62627851b95a0e8f5cc669ba3ff108f8"
    }
  },
  {
    "ts": null,
    "headline": "Semaglutide Market Forecast Report 2025-2033 | Growth Accelerates Amid Rising Awareness, Regulatory Approvals, and Strong Pipeline Advancements",
    "summary": "The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the market for semaglutide, a GLP-1 receptor agonist, is growing due to its efficacy in glycemic control and weight management. Brand names like Ozempic, Rybelsus, and Wegovy underscore its role in improving health outcomes. Increased awareness, approvals, and advanced delivery systems play pivotal roles",
    "url": "https://finnhub.io/api/news?id=cacaeab5a9d58cf9cbe3fc3c6cccefcd299e1467220dd1cf04e9ee6d8b3b85ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751449380,
      "headline": "Semaglutide Market Forecast Report 2025-2033 | Growth Accelerates Amid Rising Awareness, Regulatory Approvals, and Strong Pipeline Advancements",
      "id": 135711116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the market for semaglutide, a GLP-1 receptor agonist, is growing due to its efficacy in glycemic control and weight management. Brand names like Ozempic, Rybelsus, and Wegovy underscore its role in improving health outcomes. Increased awareness, approvals, and advanced delivery systems play pivotal roles",
      "url": "https://finnhub.io/api/news?id=cacaeab5a9d58cf9cbe3fc3c6cccefcd299e1467220dd1cf04e9ee6d8b3b85ad"
    }
  },
  {
    "ts": null,
    "headline": "Top 50 High-Quality Dividend Stocks For July 2025",
    "summary": "I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities.",
    "url": "https://finnhub.io/api/news?id=2282cab7bcf4d89b2df0b78e5bc93930757541a045dcf14c97394dad92da541c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751446607,
      "headline": "Top 50 High-Quality Dividend Stocks For July 2025",
      "id": 135710888,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1742994496/image_1742994496.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities.",
      "url": "https://finnhub.io/api/news?id=2282cab7bcf4d89b2df0b78e5bc93930757541a045dcf14c97394dad92da541c"
    }
  },
  {
    "ts": null,
    "headline": "2 Growth Stocks to Buy Hand Over Fist in July",
    "summary": "These companies are poised to produce fireworks for your portfolio over the coming years.",
    "url": "https://finnhub.io/api/news?id=d38db9f4ade9191120628781ca34ac05c990ec77aa549891530158f1e8d8d7f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751443260,
      "headline": "2 Growth Stocks to Buy Hand Over Fist in July",
      "id": 135708820,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These companies are poised to produce fireworks for your portfolio over the coming years.",
      "url": "https://finnhub.io/api/news?id=d38db9f4ade9191120628781ca34ac05c990ec77aa549891530158f1e8d8d7f3"
    }
  },
  {
    "ts": null,
    "headline": "This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk",
    "summary": "Amgen recently released the full data from a trial involving its GLP-1 drug, MariTide.  More than one-quarter of the participants on the highest dosage of the drug had to stop taking it due to adverse side effects.  There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs.",
    "url": "https://finnhub.io/api/news?id=a42bf488a4b5bd9da21e125631a47e29392ed7ccfebd714b00255a8002f14d4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751418840,
      "headline": "This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk",
      "id": 135703109,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen recently released the full data from a trial involving its GLP-1 drug, MariTide.  More than one-quarter of the participants on the highest dosage of the drug had to stop taking it due to adverse side effects.  There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs.",
      "url": "https://finnhub.io/api/news?id=a42bf488a4b5bd9da21e125631a47e29392ed7ccfebd714b00255a8002f14d4d"
    }
  }
]